Envestnet Portfolio Solutions Inc. Acquires New Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Envestnet Portfolio Solutions Inc. bought a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 7,177 shares of the biopharmaceutical company's stock, valued at approximately $216,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Victory Capital Management Inc. lifted its position in TG Therapeutics by 24.7% during the third quarter. Victory Capital Management Inc. now owns 32,679 shares of the biopharmaceutical company's stock valued at $764,000 after purchasing an additional 6,467 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of TG Therapeutics by 0.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,184,609 shares of the biopharmaceutical company's stock worth $27,708,000 after purchasing an additional 7,939 shares during the period. Citigroup Inc. raised its holdings in TG Therapeutics by 125.7% during the 3rd quarter. Citigroup Inc. now owns 168,277 shares of the biopharmaceutical company's stock valued at $3,936,000 after buying an additional 93,730 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in TG Therapeutics by 12.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 31,147 shares of the biopharmaceutical company's stock worth $729,000 after buying an additional 3,347 shares during the last quarter. Finally, Public Sector Pension Investment Board purchased a new position in TG Therapeutics during the third quarter worth $6,619,000. 58.58% of the stock is currently owned by institutional investors.

Remove Ads

TG Therapeutics Trading Up 5.5 %

TG Therapeutics stock traded up $2.07 during trading hours on Wednesday, hitting $39.82. The company had a trading volume of 4,483,390 shares, compared to its average volume of 3,078,007. The firm has a market cap of $6.25 billion, a P/E ratio of -398.16 and a beta of 2.30. The company has a 50-day moving average price of $34.94 and a two-hundred day moving average price of $30.67. TG Therapeutics, Inc. has a 1 year low of $12.93 and a 1 year high of $43.32. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.07. The company had revenue of $108.19 million for the quarter, compared to analysts' expectations of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. On average, sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

TGTX has been the subject of several analyst reports. HC Wainwright restated a "buy" rating and issued a $55.00 target price on shares of TG Therapeutics in a report on Tuesday, March 4th. StockNews.com raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $40.67.

Insider Activity at TG Therapeutics

In other news, CFO Sean A. Power sold 11,337 shares of the stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $30.29, for a total transaction of $343,397.73. Following the transaction, the chief financial officer now directly owns 670,632 shares in the company, valued at approximately $20,313,443.28. This trade represents a 1.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 10.50% of the stock is currently owned by corporate insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.